Bernie Haffey Named Chief Commercial Officer at SightLife Surgical

May 12, 2017: By Joan McKenna

SightLifeSurgicalPaul Bernard “Bernie” Haffey has joined SightLife Surgical as its first chief commercial officer.

SightLife Surgical, founded in 2016, is a Seattle-based for-profit subsidiary of SightLife that provides comprehensive services to support ophthalmic surgeons, from corneal tissue and devices to reimbursement consulting and political advocacy.

“Given our ambitions to accelerate discoveries that will benefit the cornea world, from surgeons to patients, Bernie’s background launching emerging medical technology companies, as well as his proven history of creating shareholder value, will help us reach our goal to eliminate corneal blindness by 2040,” said Monty Montoya, SightLife Surgical president and CEO.

Most recently, Haffey served as president and CEO of Nexis Vision, Inc., and president and CEO of NDO Surgical, Inc. He also served as executive vice president and chief commercial officer at Summit Technology, Inc., and as executive vice president and chief commercial officer at IntraLase Corp. In addition to his role at SightLife, Bernie serves as president of 2020 Management Consulting, Inc.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Launches Stellaris Elite for Retinal Surgery in US

Sentencing Delayed for Florida Retina Specialist Melgen

Valeant Receives FDA Complete Response Letter for Vyzulta

US FDA Clears Optovue Software for Corneal Epithelial Thickness Mapping

Ocular Therapeutix Names Daniel Bollag as Regulatory Chief

Eylea Sales Continue to Increase; Lucentis Gains New Indications

RXi Pharmaceuticals Signs Common Stock Purchase Agreement for Up to $15 Million

Allegro’s Luminate Posts Positive Results in Phase IIb Stage 2 Trial for Diabetic Macular Edema

Omeros’ Omidria Revenues Grow 71 Percent

AGTC Receives US FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa

Aerpio Shares Begin Trading on OTCQB Market

Aerie Reports FDA Concerns over Contract Manufacturer’s Plant

Valeant’s Bausch + Lomb Revenues Dip 3 percent in Q2-2017

Ocular Therapeutix Reports $66 Million in Cash, Cash Equivalents

Imprimis’ Q2-2017 Ophthalmology Revenues Increase 70 percent

Carl Zeiss Meditec’s Revenues Grow 7.5 Percent in Latest Quarter

Johnson & Johnson Vision to Acquire TearScience

Mynosys Receives $1 Million Grant from NEI to Commercialize Zepto

Ocular Therapeutix Eliminates 26 Positions; New CEO Takes Helm

Inotek Stops Development of Trabodenoson after Second Failed Study

Coming soon

2017 Glaucoma Pharmaceuticals Report: A Global Market Analysis for 2016 to 2022